H1N1 Vaccine in HIV-Infected Individuals:
Only 28% of 63 HIV-infected adults developed durable protective responses to H1N1 influenza vaccine at 6 months, compared to the rate of 56% seen in 64 controls.
|
Monovalent H1N1 vaccine in this asymptomatic HIV+ cohort was ineffective indicating the need for a different strategy for this population. |
Crum-Cianflone NF, et al.30
|
Clinical Patterns of Influenza-like Illness (ILI) Due to Human Rhinoviruses (HRV):
84 cases of HRV were genotyped in 22 children and 62 adults with ILI. Most HRV-C occurred in children. Adults with HRV-A displayed more severe symptoms and shed virus longer.
|
Species-specific and age-specific differences in symptoms and duration of shedding occur with the 3 main serotypes of HRV (A, B, C) |
Chen WJ, et al.12
|
Use of Neuraminidase Inhibitors (NI) in the Department of Defense (DoD):
NI were used for proven influenza in 23.9% of DoD members, though only 63% received NI at <48 hours of illness.
|
NI’s use was limited, not always as early as recommended, and displayed only modest benefits in this healthy population. |
Fairchok MP, et al.16
|
Self-Administration of Live attenuated Influenza Vaccine (LAIV):
A phase IV open label randomized trial found similar immunogenicity (anti-hemagglutinin antibody concentrations) in 529 subjects who self-administered LAIV vs. 548 who received vaccine from healthcare workers
|
Self-administration of LAIV was well-accepted, equally effective, and could be an option during future needs for mass immunization. |
Burgess TH, et al.29
|
Attenuation of Influenza after Vaccination:
Of 111 immunized individuals with influenza, those who developed H3N2 infection had reduced disease severity, though those with H1N1 did not show a similar benefit.
|
Though vaccines may not protect against disease, they may attenuate severity for certain strains. |
Deiss RG, et al.31
|
|
|
Potential role for this adjunct tool in supporting rapid assessment of influenza disease severity |
Powers JH, et al.14
|
Clinical Patterns of ILI with Adenovirus:
Of 43 cases of adenoviral ILI, species C predominated, primarily in young children (median 3.4 years), and were less severe than A, B, or E
|
Unique clinical patterns are associated with specific species, and may help predict disease severity |
Koren MA, et al.8
|
Phase 2 Trial Assessing Immune Plasma for Severe Acute Respiratory Infection Treatment:
Patients who received plasma had fewer serious adverse effects but no overall significant impact of time to normalization of respiratory status
|
Immune plasma was well-tolerated by patients and demonstrated the potential for outcome improvement |
Beigel JH, et al.36
|
